The technique of gene silencing using antisense oligonucleotides is of high interest to investigators involved in drug development. In theory, this technology provides a means of specifically targeting the expression of a single gene product. The ever-expanding field of antisense technology now covers a wide range of substances including oligonucleotides, peptide nucleic acids as well as small interfering ribonucleic acids or RNA interference. Antisense technology has developed over the past decade to the stage where there are now several clinical trials evaluating the safety as well as efficacy of these agents in clinical oncology. With rapid developments in synthesis of the oligonucleotides, modifications that make the oligonucleotides more stable, and identification of more tumor-specific targets, it is likely that antisense oligonucleotides will become useful in cancer therapy. These drugs appear to be well tolerated and may be combined with conventional chemotherapeutic agents for better antitumor effects.
KeywordsDocetaxel Mitoxantrone Antisense Oligonucleotide Peptide Nucleic Acid Hormone Refractory Prostate Cancer
No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.
- 13.Crooke ST. Oligonucleotide therapies. In: Wolff ME, editor. Burger’s medicinal chemistry and drug discovery. New York: Wiley and Sons, 1995: 863–900Google Scholar
- 16.Westermann P, Gross B, Hoinikis G. Inhibition of expression of SV40 virus large T antigen by antisense oligodeoxyribonucleotides. Biochim Biophys Acta 1989; 48: 85–93Google Scholar
- 30.Guvakova MA, Yakubov LA, Vlodavsky I, et al. Phosphorothioate oligodeoxyribonucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995; 270: 2620–7PubMedCrossRefGoogle Scholar
- 45.Chen HX, Marshall JL, Trocky N, et al. A phase 1 study of Bcl-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors [abstract 692]. Proc Am Soc Clin Oncol 2000; 19: 178aGoogle Scholar
- 46.Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer [abstract]. Semin Oncol 2001 Aug 28; 4Suppl. 15: 67–70Google Scholar
- 48.National Cancer Institute (NCI). Docetaxel with or without oblimersen in treating patients with non-small cell lung cancer [online]. Available from URL: http://http://www.clinicaltrials.gov [Accessed 2003 Jul 7]
- 52.ISIS™ Pharmaceuticals. Enrollment is open for an investigational anti-cancer antisense drug: OGX-011 (ISIS 112989) [online]. Available from URL: http://http://www.isispharm.com/ct_cancer.html [Accessed 2003 Jul 7]
- 54.Siu LL, Gelmon KA, Moore MJ, et al. A phase I and pharmacokinetic (PK) study of the human DNA methyltransferase (Metase) antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks [abstract 733]. Proc Am Soc Clin Oncol 2000; 19: 189aGoogle Scholar